Allspring Global Investments Holdings LLC lessened its stake in Synopsys, Inc. (NASDAQ:SNPS – Free Report) by 28.5% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 49,089 shares of the semiconductor company’s stock after selling 19,613 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Synopsys were worth $19,476,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Sankala Group LLC bought a new stake in Synopsys during the fourth quarter worth $25,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Synopsys during the 4th quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Synopsys in the 4th quarter worth approximately $28,000. Atlas Capital Advisors Inc. bought a new position in Synopsys during the fourth quarter valued at $32,000. Finally, Phillip James Consulting Co. purchased a new stake in Synopsys during the fourth quarter valued at about $36,000. Hedge funds and other institutional investors own 85.47% of the company’s stock.
Key Headlines Impacting Synopsys
Here are the key news stories impacting Synopsys this week:
- Positive Sentiment: Mizuho said Moonshot AI’s Kimi K3 release reinforces, rather than weakens, the case for agentic AI and could benefit EDA software leaders like Synopsys, prompting a “buy the dip” view after the recent selloff. Buy the dip in EDA stocks as Kimi K3 boosts agentic AI thesis: Mizuho
- Positive Sentiment: Another analysis argued Synopsys should benefit regardless of which companies win the AI race, since AI development across the industry still requires chip-design software and infrastructure. Synopsys Should Benefit No Matter Who Wins The AI Race. Here’s What Explains Its Poor Stock Performance.
- Neutral Sentiment: Technical-trading coverage said SNPS was testing an important price level and had shown signs of stabilization, suggesting traders may be watching for a reversal rather than reacting to a new business catalyst. Stock Of The Day: Will Synopsys Reverse?
- Neutral Sentiment: Broader market headlines also mentioned SNPS in the context of a firmer futures market, which may have helped sentiment somewhat, but did not add company-specific news. Stock Market Today: S&P 500, Dow Jones Futures Gain as Trump Says Iran is ‘Very, Very Badly Damaged’— Eva Live, RTX, Synopsys in Focus
Insiders Place Their Bets
Analysts Set New Price Targets
SNPS has been the subject of a number of recent research reports. BNP Paribas Exane lifted their price objective on shares of Synopsys from $425.00 to $450.00 and gave the company an “underperform” rating in a research note on Thursday, May 28th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Synopsys in a research report on Monday, June 8th. Benchmark assumed coverage on Synopsys in a research note on Wednesday, July 15th. They set a “buy” rating and a $570.00 price objective for the company. Berenberg Bank set a $633.00 target price on Synopsys in a research report on Wednesday, May 27th. Finally, Rosenblatt Securities upped their target price on Synopsys from $530.00 to $575.00 and gave the stock a “buy” rating in a research note on Tuesday, May 26th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $570.06.
Read Our Latest Stock Report on SNPS
Synopsys Stock Performance
NASDAQ:SNPS opened at $389.07 on Wednesday. The business has a 50 day moving average price of $464.07 and a 200-day moving average price of $457.23. Synopsys, Inc. has a fifty-two week low of $366.00 and a fifty-two week high of $651.73. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.32 and a current ratio of 1.43. The firm has a market cap of $74.50 billion, a PE ratio of 90.06, a price-to-earnings-growth ratio of 2.22 and a beta of 1.22.
Synopsys (NASDAQ:SNPS – Get Free Report) last issued its quarterly earnings data on Wednesday, May 27th. The semiconductor company reported $3.35 EPS for the quarter, beating the consensus estimate of $3.15 by $0.20. The firm had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.25 billion. Synopsys had a net margin of 8.91% and a return on equity of 5.83%. The company’s quarterly revenue was up 41.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.67 earnings per share. Synopsys has set its FY 2026 guidance at 14.720-14.800 EPS and its Q3 2026 guidance at 3.630-3.690 EPS. Equities research analysts predict that Synopsys, Inc. will post 10.65 earnings per share for the current year.
Synopsys Company Profile
Synopsys, Inc is a leading provider of electronic design automation (EDA) software and semiconductor intellectual property (IP) used to design, verify and manufacture integrated circuits and complex systems-on-chip (SoCs). Its product portfolio spans tools and technologies for front‑end design and synthesis, simulation and verification, physical implementation and signoff, and design-for-manufacturability, enabling chip designers to move from architecture through tape‑out.
In addition to core EDA offerings, Synopsys supplies a broad set of semiconductor IP building blocks — such as interface, memory and analog/mixed-signal cores — that customers integrate into SoCs to accelerate development.
See Also
- Five stocks we like better than Synopsys
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for Synopsys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synopsys and related companies with MarketBeat.com's FREE daily email newsletter.
